{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:31Z","timestamp":1792801351125,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91542121"],"award-info":[{"award-number":["91542121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571603"],"award-info":[{"award-number":["81571603"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006739","name":"Capital Foundation of Medical Development","doi-asserted-by":"publisher","award":["2016-2-4063"],"award-info":[{"award-number":["2016-2-4063"]}],"id":[{"id":"10.13039\/501100006739","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Commission Foundation of Beijing","award":["Z151100004015143"],"award-info":[{"award-number":["Z151100004015143"]}]},{"name":"China-Japan Friendship Hospital Funds for Young Scholars","award":["2014-3-QN-25"],"award-info":[{"award-number":["2014-3-QN-25"]}],"id":[{"id":"https:\/\/ror.org\/037cjxp13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1469-8","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T20:54:57Z","timestamp":1511556897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":159,"title":["Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Hanbo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-6881","authenticated-orcid":false,"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,25]]},"reference":[{"key":"1469_CR1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cca.2015.02.007","volume":"444","author":"X Lu","year":"2015","unstructured":"Lu X, Peng Q, Wang G. Discovery of new biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta. 2015;444:117\u201325.","journal-title":"Clin Chim Acta."},{"key":"1469_CR2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84:231\u201349.","journal-title":"Medicine (Baltimore)"},{"key":"1469_CR3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710\u20133.","journal-title":"Ann Rheum Dis."},{"key":"1469_CR4","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013;65:2954\u201362.","journal-title":"Arthritis Rheum."},{"key":"1469_CR5","doi-asserted-by":"crossref","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, et al. Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk. Arthritis Care Res. 2017;69:1771-6.","DOI":"10.1002\/acr.23188"},{"key":"1469_CR6","first-page":"169","volume":"35","author":"D Legault","year":"2008","unstructured":"Legault D, McDermott J, Crous-Tsanaclis AM, Boire G. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol. 2008;35:169\u201371.","journal-title":"J Rheumatol."},{"key":"1469_CR7","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/ar4332","volume":"15","author":"I Marie","year":"2013","unstructured":"Marie I, Hatron PY, Cherin P, Hachulla E, Diot E, Vittecoq O, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther. 2013;15:R149.","journal-title":"Arthritis Res Ther."},{"key":"1469_CR8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","volume":"11","author":"I Marie","year":"2012","unstructured":"Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11:739\u201345.","journal-title":"Autoimmun Rev."},{"key":"1469_CR9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","volume":"13","author":"JC Lega","year":"2014","unstructured":"Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014;13:883\u201391.","journal-title":"Autoimmun Rev."},{"key":"1469_CR10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis. 2006;65:242\u20135.","journal-title":"Ann Rheum Dis."},{"key":"1469_CR11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","volume":"139","author":"Y Allenbach","year":"2016","unstructured":"Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, Hervier B, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139:2131\u20135.","journal-title":"Brain."},{"key":"1469_CR12","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","volume":"3","author":"M Kadoya","year":"2016","unstructured":"Kadoya M, Hida A, Hashimoto Maeda M, Taira K, Ikenaga C, Uchio N, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016;3:e290.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1469_CR13","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","volume":"14","author":"A Ceribelli","year":"2012","unstructured":"Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis. Arthritis Res Ther. 2012;14:R97.","journal-title":"Arthritis Res Ther."},{"key":"1469_CR14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.60.2.116","volume":"60","author":"R Brouwer","year":"2001","unstructured":"Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60:116\u201323.","journal-title":"Ann Rheum Dis."},{"key":"1469_CR15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360\u201374.","journal-title":"Medicine (Baltimore)"},{"key":"1469_CR16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.md.0000217525.82287.eb","volume":"85","author":"TP O'Hanlon","year":"2006","unstructured":"O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006;85:111\u201327.","journal-title":"Medicine (Baltimore)"},{"key":"1469_CR17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BOR.0b013e3283317fa5","volume":"21","author":"K Danko","year":"2009","unstructured":"Danko K, Ponyi A, Molnar AP, Andras C, Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol. 2009;21:594\u20138.","journal-title":"Curr Opin Rheumatol."},{"key":"1469_CR18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","volume":"201","author":"L Casciola-Rosen","year":"2005","unstructured":"Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201:591\u2013601.","journal-title":"J Exp Med."},{"key":"1469_CR19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med."},{"key":"1469_CR20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403\u20137.","journal-title":"N Engl J Med."},{"key":"1469_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337\u201345.","journal-title":"Neuromuscul Disord."},{"key":"1469_CR22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626\u201336.","journal-title":"J Am Acad Dermatol."},{"key":"1469_CR23","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35\u00a0years? Chest. 2010;138:1464\u201374.","journal-title":"Chest."},{"key":"1469_CR24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/BOR.0b013e328359e780","volume":"25","author":"L Azar","year":"2013","unstructured":"Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol. 2013;25:44\u20139.","journal-title":"Curr Opin Rheumatol."},{"key":"1469_CR25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","volume":"173","author":"CO Anyanwu","year":"2015","unstructured":"Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173:969\u201374.","journal-title":"Br J Dermatol."},{"key":"1469_CR26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0885-3924(03)00162-3","volume":"25","author":"JT Farrar","year":"2003","unstructured":"Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manag. 2003;25:406\u201311.","journal-title":"J Pain Symptom Manag."},{"key":"1469_CR27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40880-015-0001-2","volume":"27","author":"W Chen","year":"2015","unstructured":"Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2\u201312.","journal-title":"Chin J Cancer Res."},{"key":"1469_CR28","first-page":"152","volume-title":"Geigy scientific tables","author":"K Diem","year":"1982","unstructured":"Diem K, Seldrup J. Medical Education Division. Poisson distribution of 95% confidence limits. In: Lentner C, editor. Geigy scientific tables, vol. 2. 8th ed. New Jersey: Ciba-Geigy Corps; 1982. p. 152.","edition":"8"},{"key":"1469_CR29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","volume":"87","author":"A Hida","year":"2016","unstructured":"Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, et al. Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87:299\u2013308.","journal-title":"Neurology."},{"key":"1469_CR30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2340\/00015555-1550","volume":"93","author":"A Kasuya","year":"2013","unstructured":"Kasuya A, Hamaguchi Y, Fujimoto M, Tokura Y. TIF1gamma-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155\/140 autoantibody. Acta Derm Venereol. 2013;93:715\u20136.","journal-title":"Acta Derm Venereol."},{"key":"1469_CR31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.38863","volume":"67","author":"P Mohassel","year":"2015","unstructured":"Mohassel P, Rosen P, Casciola-Rosen L, Pak K, Mammen AL. Expression of the dermatomyositis autoantigen transcription intermediary factor 1gamma in regenerating muscle. Arthritis Rheumatol. 2015;67:266\u201372.","journal-title":"Arthritis Rheumatol."},{"key":"1469_CR32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/rheumatology\/kes033","volume":"51","author":"A Ishikawa","year":"2012","unstructured":"Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford). 2012;51:1181\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"1469_CR33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.33402","volume":"64","author":"D Fiorentino","year":"2012","unstructured":"Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 2012;64:346\u20139.","journal-title":"Arthritis Rheum."},{"key":"1469_CR34","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1242\/jcs.126748","volume":"126","author":"L Fattet","year":"2013","unstructured":"Fattet L, Ay AS, Bonneau B, Jallades L, Mikaelian I, Treilleux I, et al. TIF1gamma requires sumoylation to exert its repressive activity on TGFbeta signaling. J Cell Sci. 2013;126:3713\u201323.","journal-title":"J Cell Sci."},{"key":"1469_CR35","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2217\/fon.15.41","volume":"11","author":"D Mattoscio","year":"2015","unstructured":"Mattoscio D, Chiocca S. SUMO pathway components as possible cancer biomarkers. Futur Oncol (London, England). 2015;11:1599\u2013610.","journal-title":"Futur Oncol (London, England)"},{"key":"1469_CR36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/RHU.0b013e31817d116f","volume":"14","author":"A Rozelle","year":"2008","unstructured":"Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol. 2008;14:285\u20138.","journal-title":"J Clin Rheumatol."},{"key":"1469_CR37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard.2006.068502","volume":"66","author":"H Chinoy","year":"2007","unstructured":"Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66:1345\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1469_CR38","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1073\/pnas.0802862105","volume":"105","author":"SG Park","year":"2008","unstructured":"Park SG, Schimmel P, Kim S. Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci USA. 2008;105:11043\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1469_CR39","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2169\/internalmedicine.56.8134","volume":"56","author":"A Mizuma","year":"2017","unstructured":"Mizuma A, Kouchi M, Netsu S, Yutani S, Kitao R, Suzuki S, et al. Paraneoplastic anti-3-hydroxy-3-methylglutary-coenzyme A reductase antibody-positive immune-mediated necrotizing myopathy in a patient with uterine cancer. Intern Med (Tokyo, Japan). 2017;56:1915\u20138.","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"1469_CR40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12907-015-0008-2","volume":"15","author":"E Gustbee","year":"2015","unstructured":"Gustbee E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirstrom K, et al. Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clin Pathol. 2015;15:8.","journal-title":"BMC Clin Pathol."},{"key":"1469_CR41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713\u201321.","journal-title":"Arthritis Rheum."},{"key":"1469_CR42","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","volume":"107","author":"JW Clendening","year":"2010","unstructured":"Clendening JW, Pandyra A, Boutros PC, Ghamrasni SE, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA. 2010;107:15051\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1469_CR43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gene.2015.09.067","volume":"576","author":"Z Qiu","year":"2016","unstructured":"Qiu Z, Yuan W, Chen T, Zhou C, Liu C, Huang Y, et al. HMGCR positively regulated the growth and migration of glioblastoma cells. Gene. 2016;576:22\u20137.","journal-title":"Gene."},{"key":"1469_CR44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gene.2016.04.029","volume":"587","author":"L Chushi","year":"2016","unstructured":"Chushi L, Wei W, Kangkang X, Yongzeng F, Ning X, Xiaolei C. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene. 2016;587:42\u20137.","journal-title":"Gene."},{"key":"1469_CR45","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","volume":"55","author":"EH Kang","year":"2016","unstructured":"Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, et al. Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford). 2016;55:1631\u201341.","journal-title":"Rheumatology (Oxford)"},{"key":"1469_CR46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1361.047","volume":"1051","author":"A Ponyi","year":"2005","unstructured":"Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann NY Acad Sci. 2005;1051:64\u201371.","journal-title":"Ann NY Acad Sci."},{"key":"1469_CR47","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.molcel.2007.12.032","volume":"29","author":"B Stielow","year":"2008","unstructured":"Stielow B, Sapetschnig A, Kruger I, Kunert N, Brehm A, Boutros M, et al. Identification of SUMO-dependent chromatin-associated transcriptional repression components by a genome-wide RNAi screen. Mol Cell. 2008;29:742\u201354.","journal-title":"Mol Cell."}],"updated-by":[{"DOI":"10.1186\/s13075-018-1549-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T00:00:00Z","timestamp":1523404800000}}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T20:55:19Z","timestamp":1511556919000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1469-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,25]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1469-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,25]]},"article-number":"259"}}